AVROBIO, Inc. (AVRO): Price and Financial Metrics


AVROBIO, Inc. (AVRO): $4.08

-0.51 (-11.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

AVRO Stock Price Chart Interactive Chart >

Price chart for AVRO

AVRO Price/Volume Stats

Current price $4.08 52-week high $20.07
Prev. close $4.59 52-week low $4.02
Day low $4.02 Volume 466,600
Day high $4.54 Avg. volume 465,796
50-day MA $5.51 Dividend yield N/A
200-day MA $8.38 Market Cap 178.10M

AVROBIO, Inc. (AVRO) Company Bio


AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.


AVRO Latest News Stream


Event/Time News Detail
Loading, please wait...

AVRO Latest Social Stream


Loading social stream, please wait...

View Full AVRO Social Stream

Latest AVRO News From Around the Web

Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.

AVROBIO to Present at Two Upcoming Investor Conferences in November

CAMBRIDGE, Mass., November 09, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences:

Yahoo | November 9, 2021

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

CAMBRIDGE, Mass., November 08, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher disease type 1 at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) on Nov. 21-23, 2021, in Sydney, Australia.

Yahoo | November 8, 2021

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., November 05, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 120,000 shares of the company’s common stock to the company’s new Chief Medical Officer, Essra Ridha, M.D., as an inducement award under the company’s 2019 Inducement Plan. The grant was made in accordance with Nasdaq Lis

Yahoo | November 5, 2021

AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., November 04, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended Sept. 30, 2021, and provided a business update.

Yahoo | November 4, 2021

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

CAMBRIDGE, Mass., November 03, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome, a rare and seriously debilitating lysosomal disorder that primarily affects young boys.

Yahoo | November 3, 2021

Read More 'AVRO' Stories Here

AVRO Price Returns

1-mo -27.40%
3-mo -38.74%
6-mo -54.41%
1-year -70.92%
3-year -84.77%
5-year N/A
YTD -70.73%
2020 -30.75%
2019 20.90%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6929 seconds.